Skip to main content
SpringerLink
Log in

Renal Disease

  • Chapter
  • First Online:
Book cover Textbook of Vascular Medicine

  • 1696 Accesses

Abstract

Chronic kidney disease (CKD) is common affecting 5–10% of the population. In clinical practice, classification of CKD is derived from kidney function measured as estimated glomerular filtration rate. CKD may progress towards end-stage kidney disease (ESKD) requiring treatment with dialysis or kidney transplantation. Treatable risk factors to reduce the risk of CKD progression include hypertension, proteinuria and therapy aimed at specific primary renal diseases. Patients with CKD and ESKD are at elevated cardiovascular risk. Some of this elevated cardiovascular risk can be attributed to a high prevalence of conventional cardiovascular risk factors being present in patients with CKD. However, a number of CKD-specific risk factors for cardiovascular disease are present including proteinuria, abnormalities of calcium-phosphate metabolism, left ventricular hypertrophy and anaemia. Targeting renal fibrosis may lead to fewer patients developing progressive CKD in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.

    Article  Google Scholar 

  2. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

    Article  Google Scholar 

  3. Kerr M, Bray B, Medcalf J, O’Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(Suppl 3):iii73–80.

    Article  Google Scholar 

  4. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28(8):463–8.

    Article  CAS  Google Scholar 

  5. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356(9224):147–52.

    Article  CAS  Google Scholar 

  6. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    Article  CAS  Google Scholar 

  7. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123(10):754–62.

    Article  CAS  Google Scholar 

  8. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.

    Article  CAS  Google Scholar 

  9. Li PK, Weening JJ, Dirks J, et al. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int Suppl. 2005;94:S2–7.

    Article  Google Scholar 

  10. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1984;108(5):1347–52.

    Article  CAS  Google Scholar 

  11. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777–82.

    Article  CAS  Google Scholar 

  12. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction – the Hoorn Study. Kidney Int Suppl. 2004;92:S42–4.

    Article  Google Scholar 

  13. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–8.

    Article  CAS  Google Scholar 

  14. Lambers Heerspink HJ, Kropelin TF, Hoekman J, de Zeeuw D. Reducing albuminuria as surrogate endpoint C. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol. 2015;26(8):2055–64.

    Article  Google Scholar 

  15. Papademetriou V, Lovato L, Doumas M, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87(3):649–59.

    Article  Google Scholar 

  16. Mann JF, Rossing P, Wiecek A, Rosivall L, Mark P, Mayer G. Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs? Nephrol Dial Transplant. 2015;30(Suppl 4):iv1–5.

    Article  CAS  Google Scholar 

  17. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.

    Article  CAS  Google Scholar 

  18. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

    Article  CAS  Google Scholar 

  19. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378(9800):1419–27.

    Article  Google Scholar 

  20. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.

    Article  Google Scholar 

  21. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11(7):1277–85.

    Article  CAS  Google Scholar 

  22. Edwards NC, Moody WE, Yuan M, et al. Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease. Am J Cardiol. 2015;115(9):1311–7.

    Article  Google Scholar 

  23. Patel RK, Oliver S, Mark PB, et al. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin J Am Soc Nephrol. 2009;4(9):1477–83.

    Article  Google Scholar 

  24. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9(6):1018–22.

    CAS  PubMed  Google Scholar 

  25. McMahon AC, Greenwald SE, Dodd SM, Hurst MJ, Raine AE. Prolonged calcium transients and myocardial remodelling in early experimental uraemia. Nephrol Dial Transplant. 2002;17(5):759–64.

    Article  CAS  Google Scholar 

  26. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10–7.

    Article  CAS  Google Scholar 

  27. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.

    Article  CAS  Google Scholar 

  28. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408.

    Article  CAS  Google Scholar 

  29. Denby L, Ramdas V, Lu R, et al. MicroRNA-214 antagonism protects against renal fibrosis. J Am Soc Nephrol. 2014;25(1):65–80.

    Article  CAS  Google Scholar 

  30. Denby L, Ramdas V, McBride MW, et al. miR-21 and miR-214 are consistently modulated during renal injury in rodent models. Am J Pathol. 2011;179(2):661–72.

    Article  CAS  Google Scholar 

  31. Sugimoto H, LeBleu VS, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med. 2012;18(3):396–404.

    Article  CAS  Google Scholar 

  32. Huang L, Haylor JL, Hau Z, et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int. 2009;76(4):383–94.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK

    Patrick B. Mark

  2. BHF Centre for Cardiovascular Sciences, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

    Laura Denby

Authors
  1. Patrick B. Mark
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Denby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick B. Mark .

Editor information

Editors and Affiliations

  1. Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK

    Rhian M. Touyz

  2. Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK

    Christian Delles

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mark, P.B., Denby, L. (2019). Renal Disease. In: Touyz, R., Delles, C. (eds) Textbook of Vascular Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-16481-2_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16481-2_38

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16480-5

  • Online ISBN: 978-3-030-16481-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation